Evercore ISI Lowers ICON Public (NASDAQ:ICLR) Price Target to $330.00

ICON Public (NASDAQ:ICLR) had its price target lowered by analysts at Evercore ISI from $350.00 to $330.00 in a report issued on Friday, Benzinga reports. The firm currently has an “outperform” rating on the medical research company’s stock. Evercore ISI’s price target points to a potential upside of 7.04% from the stock’s previous close.

Several other research analysts have also recently issued reports on the company. Barclays lifted their target price on ICON Public from $325.00 to $355.00 and gave the company an “overweight” rating in a research report on Friday, February 23rd. Truist Financial lifted their target price on ICON Public from $357.00 to $367.00 and gave the company a “buy” rating in a research report on Friday, February 23rd. Robert W. Baird lifted their target price on ICON Public from $362.00 to $363.00 and gave the company an “outperform” rating in a research report on Friday. TD Cowen lifted their target price on ICON Public from $343.00 to $349.00 and gave the company a “buy” rating in a research report on Friday. Finally, Mizuho reissued a “buy” rating and issued a $346.00 price objective on shares of ICON Public in a research report on Thursday, April 4th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, ICON Public presently has an average rating of “Moderate Buy” and a consensus target price of $321.64.

ICON Public Trading Up 2.7 %

NASDAQ ICLR opened at $308.31 on Friday. The company has a market cap of $25.44 billion, a price-to-earnings ratio of 37.51, a P/E/G ratio of 1.42 and a beta of 1.15. ICON Public has a 52 week low of $181.92 and a 52 week high of $344.77. The business has a 50 day moving average price of $318.89 and a 200-day moving average price of $283.09. The company has a quick ratio of 1.21, a current ratio of 1.21 and a debt-to-equity ratio of 0.36.

ICON Public (NASDAQ:ICLR) last released its quarterly earnings data on Wednesday, February 21st. The medical research company reported $3.40 EPS for the quarter, beating the consensus estimate of $3.27 by $0.13. The firm had revenue of $2.07 billion during the quarter, compared to the consensus estimate of $2.08 billion. ICON Public had a return on equity of 11.70% and a net margin of 8.30%. As a group, equities analysts expect that ICON Public will post 14.4 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ICLR. Steph & Co. lifted its position in shares of ICON Public by 4.6% during the 3rd quarter. Steph & Co. now owns 1,670 shares of the medical research company’s stock valued at $411,000 after buying an additional 73 shares during the last quarter. Whittier Trust Co. lifted its position in shares of ICON Public by 58.6% during the 3rd quarter. Whittier Trust Co. now owns 2,544 shares of the medical research company’s stock valued at $626,000 after buying an additional 940 shares during the last quarter. Kornitzer Capital Management Inc. KS lifted its position in shares of ICON Public by 17.5% during the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 49,660 shares of the medical research company’s stock valued at $12,229,000 after buying an additional 7,385 shares during the last quarter. NBC Securities Inc. bought a new stake in shares of ICON Public during the 3rd quarter valued at $174,000. Finally, Motco raised its stake in shares of ICON Public by 766.4% during the 3rd quarter. Motco now owns 1,291 shares of the medical research company’s stock valued at $318,000 after purchasing an additional 1,142 shares during the period. Hedge funds and other institutional investors own 95.61% of the company’s stock.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.